Piper Sandler analyst Joseph Catanzaro initiated coverage of Revolution Medicines with an Overweight rating and $43 price target. The analyst views the company’s multi-RAS inhibitor RMC-6236 as “significantly de-risked” following initial Phase I data. Piper believes RMC-6236 has multiple blockbuster opportunities and expects significant share appreciation with mature data later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines price target raised to $44 from $28 at H.C. Wainwright
- Revolution Medicines files automatic mixed securities shelf
- Revolution Medicines price target raised to $42 from $41 at Wedbush
- Revolution Medicines sees FY24 GAAP net loss $480M-$520M
- Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
